Depressive Disorder, Major clinical trials
The registry lists 3,046 studies for Depressive Disorder, Major across more than 10 countries. 592 are recruiting or about to start. 2,324 of them are mainly about Depressive Disorder, Major (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
ClinicalTrials.gov finds 3,664 studies for Depressive Disorder, Major. How that becomes 3,034 here
This page counts the studies the registry files under Depressive Disorder, Major, and those it files under no condition that list Depressive Disorder, Majorthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 3,664Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −154List Depressive Disorder, Major as a condition, but the registry did not file them under itMost often written as “Depression - Major Depressive Disorder” (127), “Major Depression Disorder” (5), and “Major Depressive Disorder With Psychotic Features” (4). The registry filed them under other conditions only, most often Depression (83) and Anxiety Disorders (52).
- −476Match it another way166 name it in the title, 7 in a keyword, and 303 by a synonym or other text the search reads.
- 3,034The count on this page63 of them list Depressive Disorder, Major in their own words; the registry filed them under no condition.
Get an email when these change. Save the Depressive Disorder, Major studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Massachusetts General Hospital (88) · National Institute of Mental Health (NIMH) (65) · Eli Lilly and Company (58) · New York State Psychiatric Institute (50) · Centre for Addiction and Mental Health (48) · Janssen Research & Development, LLC (39) · Shanghai Mental Health Center (39) · Stanford University (39)
What is being tested here
Drugs under test in Depressive Disorder, Major studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Ketamine | 21 | 13 | 89 |
| Psilocybin | 10 | 4 | 30 |
| Escitalopram | 6 | 21 | 99 |
| Sertraline | 5 | 6 | 42 |
| Esketamine | 5 | 7 | 17 |
| Osavampator | 5 | 5 | 6 |
| Fluoxetine | 3 | 6 | 29 |
| Nitrous Oxide | 3 | 1 | 9 |
| Pregnenolone | 3 | 0 | 8 |
| Lumateperone | 3 | 7 | 7 |
Drug classes tested here SSRIs 15 open · Serotonin receptor agonists 14 open · Psychedelics 14 open · Antipsychotics 8 open · Inhaled anesthetics 3 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms · Phase 3 · Janssen Research & Development, LLC
- Jan 2027An Open-Label Study of Azetukalner in Major Depressive Disorder · Phase 3 · Xenon Pharmaceuticals Inc.
- Feb 2027Sustained Mood Improvement With Laughing Gas Exposure · Phase 3 · Women's College Hospital
- Mar 2027Understanding and Treating Suicidal Ideation With Ketamine · Phase 3 · The Royal's Institute of Mental Health Research
- Mar 2027Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients · Phase 3 · Tanta University
- Apr 2027Biomarker-guided rTMS for Treatment Resistant Depression · Phase 3 · Weill Medical College of Cornell University
- Apr 2027Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder · Phase 3 · Intra-Cellular Therapies, Inc.
- May 2027A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) · Phase 3 · Xenon Pharmaceuticals Inc.
- Jun 2027A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder · Phase 3 · Cybin IRL Limited
- Jul 2027The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder · Phase 3 · Sunshine Lake Pharma Co., Ltd.
Who these studies take
Of the 412 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 293 (71%) stop at 75 or younger. 55 (13%) take children under 18. 11 (3%) are for women only and 1 (<1%) for men only; 98 (24%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 12 (3%) | 12 (3%) |
| 18 | 346 (84%) | 336 (82%) |
| 30 | 353 (86%) | 346 (84%) |
| 40 | 351 (85%) | 344 (83%) |
| 50 | 342 (83%) | 338 (82%) |
| 65 | 300 (73%) | 296 (72%) |
| 75 | 132 (32%) | 129 (31%) |
| 85 | 104 (25%) | 101 (25%) |
Across all 3,046 studies, recruiting or not: 71% stop at 75 or younger and 57% at 65; 9% take children; 4% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Depressive Disorder, Major studies take
Of 195 phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 22 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 16 mo5–45 · 88 studies | 5 mo1–12 · 40 studies | 43 mo16–… · 48 studies |
| Phase 1/2 | 36 mo18–75 · 31 studies | — | — |
| Phase 2 | 22 mo14–37 · 195 studies | 17 mo11–23 · 96 studies | 35 mo23–57 · 99 studies |
| Phase 2/3 | 46 mo28–56 · 16 studies | — | — |
| Phase 3 | 27 mo21–36 · 124 studies | 26 mo20–33 · 95 studies | — |
| Phase 4 | 35 mo20–58 · 98 studies | — | 44 mo25–60 · 79 studies |
| Interventional, no phase | 33 mo17–55 · 688 studies | 18 mo9–36 · 40 studies | 35 mo19–55 · 648 studies |
| Observational | 38 mo21–67 · 150 studies | 21 mo14–33 · 29 studies | 46 mo29–73 · 121 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting10
- Effects of rTMS Compared to SSRI as Early Treatment of Depression (Early-TMS)Nov 10, 2026NCT06545474
- Behavioural Activation Therapy and Ketamine for Treatment-Resistant DepressionNov 9, 2026NCT07801703
- Student Precarity and PsychiatryNov 6, 2026NCT07618208
- EEG-Guided Transcranial Magnetic Stimulation for Adults With DepressionNov 3, 2026NCT07862205
- Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive DisorderOct 30, 2026NCT07593222
Show 5 moreShow fewer
- Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101Oct 30, 2026NCT07785102
- Ketogenic Diet and Neuromodulation in Treatment Resistant DepressionOct 28, 2026NCT07376018
- Tracking Response to Antidepressants in Advance of Investigational TrialsOct 27, 2026NCT04748276
- Implementation of a Multiple Intervention to Promote Healthy Lifestyles in Patients With DepressionOct 27, 2026NCT06990035
- Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use DisorderOct 26, 2026NCT07405606
Results posted3
- XEN1101 for Major Depressive DisorderNov 6, 2026NCT04827901
- SMART Trial to Predict Anhedonia Response to Antidepressant TreatmentOct 30, 2026NCT05537584
- Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality DisorderOct 29, 2026NCT05399498
Stopped5
- Acute Intermittent Hypoxia Therapy for DepressionWithdrawnNov 10, 2026NCT07921654
- Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple SclerosisWithdrawnNov 6, 2026NCT06329414
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment FailureTerminatedNov 5, 2026NCT05603104
- A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual InsomniaTerminatedNov 4, 2026NCT02669030
- Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One DayWithdrawnNov 2, 2026NCT03986658
Newly registered34
- Longitudinal Assessment of Biomarkers Among Patients With MDDNov 12, 2026NCT07931001
- Nature-Based Exercise for Major Depressive DisorderNov 12, 2026NCT07931443
- Health Assessment in People With Severe Mental IllnessNov 12, 2026NCT07931456
- Unveiling Maternal-fetal BRAin-body Interactions in Pregnant WOmen Affected by DepressionNov 12, 2026NCT07932093
- Predicting Transitions From Depression to Wellbeing Through a Network-based Operationalization of PlasticityNov 12, 2026NCT07933276
Show 29 moreShow fewer
- A Study of Brenipatide in Participants With Major Depressive DisorderNov 10, 2026NCT07928245
- Transcranial Magnetic Therapy (TMS) for Treatment of Perinatal DepressionNov 10, 2026NCT07928908
- Phase-Locked Accelerated Intermittent Theta Burst Stimulation for Treatment-Resistant DepressionNov 10, 2026NCT07930000
- Neuromodulation of Motivation and Reward OscillationsNov 9, 2026NCT07924852
- Individualized Temporally Interfering Electrical Stimulation in Major Depressive DisorderNov 9, 2026NCT07924917
- Individualized Temporal Interference Stimulation for Reward Processing in Late-Life DepressionNov 9, 2026NCT07925047
- Emotional Reactivity in Severe Alcohol Use Disorder and Major Depressive Disorder Using Eye-tracking, Physiological, and Interoceptive Measures (ERAD)Nov 9, 2026NCT07925281
- Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood ExperiencesNov 6, 2026NCT07921446
- Acute Intermittent Hypoxia Therapy for DepressionNov 6, 2026NCT07921654
- Affective Cognitive Training in Mood Disorders and High-risk RelativesNov 5, 2026NCT07920302
- Dupilumab in Major Depressive DisorderNov 2, 2026NCT07908563
- Neurostructural and Biochemical Signatures of Tobacco Smoking in Mood DisordersNov 2, 2026NCT07910318
- Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression.Oct 30, 2026NCT07906496
- Validation of Wearable Core Body Temperature-Based Circadian Rhythm Digital BiomarkersOct 29, 2026NCT07905378
- A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive DisorderOct 28, 2026NCT07901179
- Psilocybin for Depression in VeteransOct 26, 2026NCT07895134
- Neural Mechanisms of Real-world Emotions and InternalizingOct 23, 2026NCT07891624
- REM Sleep Disruption and Its Potential Uses in Depression ManagementOct 23, 2026NCT07891806
- Temporal Interference Stimulation in Major Depressive Disorder: A Pilot Feasibility StudyOct 22, 2026NCT07888387
- Testing a Non-Deceptive Placebo Intervention for Subclinical Depressive SymptomsOct 22, 2026NCT07889908
- Evaluation of a Multi-Layered Digital Phenotyping, Digital Safety Plan, and Pharmacogenomic Intervention for Suicide Prevention in Adults With DepressionOct 21, 2026NCT07885722
- Dual Neuromodulation for Depression: Boosting TMS With tESOct 19, 2026NCT07879924
- Digital Phenotypes for Predicting Depression_ValidationOct 19, 2026NCT07880015
- French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy ControlsOct 19, 2026NCT07881016
- A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental IllnessOct 16, 2026NCT07879131
- Feasibility and Preliminary Outcomes of Compassion-Focused Group Therapy for Depression and AnxietyOct 15, 2026NCT07876453
- Comparing 10 Hz rTMS and iTBS for Adolescent DepressionOct 14, 2026NCT07873060
- Digital Single-Session Cognitive Behavioural Therapy in Healthy AdultsOct 14, 2026NCT07873905
- Cortical rTMS as a Treatment for DepressionOct 13, 2026NCT05487911
Studies
Recruiting first, then most recently updated. Showing 50 of 3,046. Browse all 3,046 → or search them.
- Nature-Based Exercise for Major Depressive DisorderNot yet recruitingNCT07931443Not applicable1 country
- Unveiling Maternal-fetal BRAin-body Interactions in Pregnant WOmen Affected by DepressionRecruitingNCT07932093Not applicable3 countries
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersRecruitingNCT00018057Phase 21 country
- Precision Depression Adalimumab TrialRecruitingNCT07845604Phase 21 country
- Longitudinal Assessment of Biomarkers Among Patients With MDDRecruitingNCT079310011 country
- Sensory Synchronized Imaging and NeuromodulationNot yet recruitingNCT06548113Not applicable1 country
- Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major DepressionRecruitingNCT03973268Phase 11 country
- Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood ExperiencesNot yet recruitingNCT07921446Not applicable
- Health Assessment in People With Severe Mental IllnessRecruitingNCT079314561 country
- VR Pupillometry in Cognitive ImpairmentRecruitingNCT074023561 country
- Real-world Clinical Response to Trazodone in Italy, Poland, and RomaniaRecruitingNCT073776821 country
- Effect of TMS Treatment on Defense Mechanisms and Functionality in Patients With DepressionNot yet recruitingNCT078539891 country
- Predicting Transitions From Depression to Wellbeing Through a Network-based Operationalization of PlasticityNot yet recruitingNCT07933276
- The Role of mGluR5 in CBT-IRecruitingNCT07076342Phase 41 country
- Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With DepressionRecruitingNCT05450432Phase 41 country
- An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)Enrolling by invitationNCT07161700Phase 27 countries
- A Study of Brenipatide in Participants With Major Depressive DisorderNot yet recruitingNCT07928245Phase 28 countries
- Effects of rTMS Compared to SSRI as Early Treatment of Depression (Early-TMS)RecruitingNCT06545474Not applicable1 country
- A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)RecruitingNCT07065240Phase 27 countries
- Regulated Stimulation for Optimized Network Activity and Therapeutic EquilibriumRecruitingNCT07594483Not applicable1 country
- Neuromodulation of Motivation and Reward OscillationsRecruitingNCT07924852Not applicable1 country
- Behavioural Activation Therapy and Ketamine for Treatment-Resistant DepressionRecruitingNCT07801703Phase 2/31 country
- Emotional Reactivity in Severe Alcohol Use Disorder and Major Depressive Disorder Using Eye-tracking, Physiological, and Interoceptive Measures (ERAD)RecruitingNCT079252811 country
- Individualized Temporally Interfering Electrical Stimulation in Major Depressive DisorderRecruitingNCT07924917Not applicable1 country
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)RecruitingNCT07592689Phase 31 country
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderRecruitingNCT03065335Phase 11 country
- Individualized Temporal Interference Stimulation for Reward Processing in Late-Life DepressionNot yet recruitingNCT07925047Not applicable1 country
- Optimizing Treatment for Depressed Parents of Children With Emotional and Behavioural ProblemsRecruitingNCT07749521Not applicable1 country
- Understanding and Treating Suicidal Ideation With KetamineRecruitingNCT06891300Phase 2/31 country
- Natural History of Depression, Bipolar Disorder and Suicide RiskRecruitingNCT064621961 country
- Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderRecruitingNCT06592833Phase 21 country
- Student Precarity and PsychiatryRecruitingNCT076182081 country
- Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital TherapeuticsRecruitingNCT05877885Not applicable1 country
- Affective Cognitive Training in Mood Disorders and High-risk RelativesRecruitingNCT07920302Not applicable1 country
- ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseRecruitingNCT07284667Phase 21 country
- Expressive Arts Therapy in Major Depression: An RCTNot yet recruitingNCT07919288Not applicable
- A Study of Brenipatide in Adult Participants With Major Depressive DisorderRecruitingNCT07412756Phase 315 countries
- Efficacy of Statins Among Major Depressive DisorderRecruitingNCT06698666Phase 31 country
- Peer-Delivered Behavioral Activation in a CCBHCRecruitingNCT07219394Not applicable1 country
- Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of DepressionRecruitingNCT06559826Phase 21 country
- Evaluation of the Impact of the EDIT-B® Blood Test on the Health Status of Patients Presenting a Major Depressive Episode. Clinical Utility and Medico-Economic AspectsRecruitingNCT06507787Not applicable1 country
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsRecruitingNCT06559306Phase 316 countries
- Defining Neurobiological Links Between Substance Use and Mental IllnessRecruitingNCT05538910Not applicable1 country
- Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderRecruitingNCT05850689Phase 37 countries
- Mechanisms of Repeated Real-time Biofeedback With 7-Tesla MRI in DepressionRecruitingNCT07694076Not applicable1 country
- EEG-Guided Transcranial Magnetic Stimulation for Adults With DepressionRecruitingNCT07862205Not applicable1 country
- A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive DisorderRecruitingNCT07775300Phase 315 countries
- A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderRecruitingNCT07227454Phase 37 countries
- A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive DisorderRecruitingNCT07573176Phase 37 countries
- A Study of Lumateperone Versus Placebo in Participants With Major Depressive DisorderNot yet recruitingNCT07747389Phase 3